ClinicalTrials.gg

Hyperphosphatemia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 173 studies for Hyperphosphatemia across more than 10 countries. 16 are recruiting or about to start. 104 of them are mainly about Hyperphosphatemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Status

Completed
121
Status unknown
15
Terminated
14
Recruiting
13
Not yet recruiting
3
Active, not recruiting
3

Phase

Phase 3
60
Phase 2
34
Phase 4
18
Phase 1
12

Where

United States
56
Japan
41
China
18
Germany
18
United Kingdom
18
Italy
13

Who develops what

Add Hyperphosphatemia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 3 companies, 3 with this as their studies’ main aim; 2 with a live phase 3 study; 5 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
SevelamerRecent, repeated
Evidence
  • NCT07030595 · Alebund Pharmaceuticals · Phase 3 · comparator · “Sevelamer carbonate (Renvela®)” · registered Jun 2025
  • NCT06664125 · Jemincare · Phase 2 · live · comparator · “Sevelamer carbonate” · registered Oct 2024
  • NCT05764590 · Alebund Pharmaceuticals · Phase 2 · comparator · “Sevelamer Carbonate” · registered Feb 2023
  • NCT04551300 · Shanghai Alebund Pharmaceuticals Limited · Phase 2 · comparator · “Sevelamer Carbonate” · registered Aug 2020
  • NCT04456803 · Sinomune Pharmaceutical Co., Ltd · Phase 3 · comparator · “Sevelamer carbonate tablet” · registered Jun 2020
Sanofi71% of its industry studiesEU: Sanofi (EMA 2000)23 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Nov 2026 est.TS-172 · Taisho Pharmaceutical Co., Ltd. · Phase 3 main aimNCT07548840 A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis — primary endpoint: Achievement rate of the target serum phosphorus level · 34 enrolled
  • 22 Dec 2026 est.TS-172 · Taisho Pharmaceutical Co., Ltd. · Phase 3 main aimNCT07285291 A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders — primary endpoint: Achievement rate of the target serum phosphorus level · 100 enrolled
  • 28 Feb 2027 est.AP-306 · R1 Therapeutics · Phase 2 main aimNCT06712654 A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia — primary endpoint: To investigate the ability of AP306 at different fixed doses to lower serum phosphate in participants with hyperphosphatemia receiving maintenance hemodialysis · 168 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hyperphosphatemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

7studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7, phase 3 first

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger. 4 (31%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (23%) take healthy volunteers.

Recruiting studies that take each age, of 13
AgeWomenMen
103 (23%)3 (23%)
1811 (85%)11 (85%)
3011 (85%)11 (85%)
4011 (85%)11 (85%)
5011 (85%)11 (85%)
6511 (85%)11 (85%)
7511 (85%)11 (85%)
8511 (85%)11 (85%)

Across all 173 studies, recruiting or not: 17% stop at 75 or younger and 10% at 65; 14% take children; 0% are for women only and 1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hyperphosphatemia studies take

Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 27 mo6–10 · 13 studies——
Phase 315 mo8–22 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 173. Browse all 173 → or search them.